The Japanese Association for Thoracic Surgery has conducted annual surveys of thoracic surgery throughout Japan since 1987 to determine the statistics regarding the number of procedures according to operative category. Here, we have summarized the results from our annual survey of thoracic surgery performed during 2012.**Table 1** Questionnaires sent out and received back by the end of December 2013Sent outReturnedResponse rate (%)(A) Cardiovascular surgery60158397.0(B) General thoracic surgery80277796.9(C) Esophageal surgery58255595.4**Table 2** Categories subclassified according to the number of operations performedNumber of operations performedCategoryCardiovascular surgeryGeneral thoracic surgery039411--24469225--49999250--99163193100--14986134150--19960107≧20090118Total583777Number of operations performedEsophageal surgery0861--4995--98110--1910520--294830--393540--4930≧5071Total555Fig. 1Cardiovascular surgery, *IHD* ischemic heart disease

The incidence of hospital mortality was added to the survey to determine the nationwide status, which has contributed to the Japanese surgeons to understand the present status of thoracic surgery in Japan and to make progress to improve operative results by comparing their work with those of others. The Association was able to gain a better understanding of the present problems as well as future prospects, which has been reflected to its activity including education of its members. Thirty-day mortality (so-called "operative mortality) is defined as death within 30 days of operation regardless of the patient's geographic location and even though the patient had been discharged from the hospital.

Hospital mortality is defined as death within any time interval after an operation if the patient had not been discharged from the hospital. Hospital-to-hospital transfer is not considered discharge: transfer to a nursing home or a rehabilitation unit is considered hospital discharge unless the patient subsequently dies of complications of the operation. The definitions of the Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity of the Society of Thoracic Surgeons and the American Association for Thoracic Surgery (Edmunds et al. Ann Thorac Surg 1996;62:932--5; J Thorac Cardiovasc Surg 1996;112:708--11).

Thoracic surgery was classified into three categories---cardiovascular, general thoracic, and esophageal surgery---and the patient data were examined and analyzed for each group. Access to the computerized data is offered to all members of this Association. We honor and value all member's continued kind support and contributions (Tables 1, 2).**Table 1** Congenital (total; 9,558)(1) CPB (+) (total; 7,171)NeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1PDA1500020004000241 (4.2)01 (4.2)451 (2.2)01 (2.2)2Coarctation (simple)700013000170007000440003 +VSD322 (6.3)02 (6.3)3400080002000762 (2.6)02 (2.6)4 +DORV2001 (50.0)3000200000007001 (14.3)5 +AVSD5000400010000000100006 +TGA31 (33.3)01 (33.3)30001000000071 (14.3)01 (14.3)7 +SV92 (22.2)02 (22.2)700040000000202 (10.0)02 (10.0)8 +Others2000500040001000120009Interrupt. of Ao (simple)100021 (50.0)01 (50.0)2000100061 (16.7)01 (16.7)10 +VSD252 (8.0)02 (8.0)16000400010000552 (3.6)02 (3.6)11 +DORV31 (33)01 (33.3)40002000000091 (11.1)01 (11.1)12 +Truncus21 (50.0)01 (50.0)20000000000041 (25.0)01 (25.0)13 +TGA2000100000000000300014 +Others4000101 (10.0)01 (10.0)20001000171 (5.9)01 (5.9)15Vascular ring0000400030000000700016PS100015000140004001 (25.0)34001 (2.9)17PAIVS or critical PS12000501 (2.0)01 (2.0)550002001 (50.0)1191 (0.8)02 (1.7)18TAPVR1269 (7.1)015 (11.9)491 (2)2 (4.08)2 (4.1)8000000018310 (5)2 (1.1)17 (9)19PAPVR ± ASD0000400052000290008500020ASD111 (9.1)01 (9.1)540006930005732 (0.3)1 (0.2)2 (0.3)1,3313 (0.2)1 (0.08)3 (0.2)21Cor triatriatum1000132 (15.4)02 (15.4)30004000212 (9.5)02 (9.5)22AVSD (partial)11 (100.0)01 (100.0)191 (5.3)01 (5.3)4000013000732 (2.7)02 (2.7)23AVSD (complete)4001 (25.0)1085 (4.6)05 (4.6)6900040001855 (2.7)06 (3.2)24 +TOF or DORV000061 (16.7)02 (33.3)210003000301 (3.3)02 (6.7)25 +Others1000101 (10.0)01 (10.0)80001000201 (5.0)01 (5.0)26VSD (subarterial)30001280001970002900035700027VSD (perimemb./muscular)1000077001 (0.13)0390000900001,26001 (0.1)028VSD + PS0000390003300070007900029DCRV ± VSD20001600039000190007600030Aneurysm of sinus valsalva000060001000240003100031TOF151 (6.7)01 (6.7)1680002312 (0.9)02 (0.9)22002 (9.1)4363 (0.7)05 (1.1)32PA + VSD4000781 (1.3)01 (1.3)1253 (2.4)05 (4.0)90002164 (1.9)06 (2.8)33DORV171 (5.9)01 (5.9)911 (1.1)03 (3.3)1122 (1.8)02 (1.8)31 (33.3)01 (33.3)2235 (2.2)07 (3.1)34TGA (simple)1012 (2.0)03 (3.0)12000000040001172 (1.7)03 (2.6)35 +VSD441 (2.3)01 (2.3)171 (5.9)01 (5.9)20000000632 (3.2)02 (3.2)36 VSD + PS400080002600020004000037Corrected TGA200011000421 (2.4)01 (2.4)13000681 (1.5)01 (1.5)38Truncus arteriosus4000262 (7.7)03 (11.5)120001000432 (4.7)03 (7.0)39SV275 (18.5)08 (29.6)2197 (3.2)011 (5.0)2824 (1.4)09 (3.2)212 (9.5)02 (9.5)54918 (3.3)030 (5.5)40TA2000300005300050009000041HLHS4510 (22.2)010 (22.2)13011 (8.5)1 (0.77)15 (11.5)71000000024621 (8.5)1 (11.7)25 (10.2)42Aortic valve lesion73 (42.9)03 (42.9)16000753 (4.0)03 (4.0)191 (5.3)01 (5.3)1177 (6.0)07 (6.0)43Mitral valve lesion21 (50.0)01 (50.0)56002 (3.6)751 (1.3)01 (1.3)140001472 (1.4)04 (2.7)44Ebstein101 (10.0)01 (10.0)171 (5.9)01 (5.9)3100012000702 (2.9)02 (2.9)45Coronary disease00001100016000130004000046Others11001 (9.1)273 (11.1)03 (11.1)342 (5.9)02 (5.9)14000865 (5.8)06 (7.0)47Redo VSD000060001000070002300048PS release0000800042000230007300049RV-PA conduit replace00003000681 (1.5)01(1.5)17001 (5.9)881 (1.1)02 (2.3)50Others1000626 (9.7)07 (11.3)1212 (1.7)04 (3.3)461 (2.2)01 (2.2)2309 (3.9)012 (5.2)Total58045 (7.8)058 (10.0)2,39347 (2.0)4 (0.17)63 (2.6)3,10521 (0.7)030 (1.0)1,0938 (0.7)1 (0.1)13 (1.2)7,171121 (1.7)5 (0.1)164 (2.3)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass, *PDA* patient ductus arteriosus, *VSD* ventricular septal defect, *DORV* double outlet right ventricle, *AVSD* atrioventricular septal defect, *TGA* transposition of great arteries, *SV* single ventricle, *Interupt. of Ao.*, interrupted aortic arch, *PS* pulmonary stenosis, *PA-IVS* pulmonary atresia with intact ventricular septum, *TAPVR* total anomalous pulmonary venous return, *PAPVR* partial anomalous pulmonary venous return, *ASD* atrial septal defect, *TOF* tetralogy of Fallot, *DCRV* double-chambered right ventricle, *TA* tricuspid atresia, *HLHS* hypoplastic left heart syndrome, *RV-PA* right ventricle--pulmonary artery(2) CPB (−) (total; 2,387)NeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1PDA3582 (0.6)03 (0.8)225002 (0.9)4600010006302 (0.3)05 (0.8)2Coarctation (simple)210001400040001000400003 +VSD381 (2.6)1 (2.6)1 (2.6)261 (3.8)01 (3.8)00000000642 (3.1)1 (1.6)2 (3.1)4 +DORV5001 (20.0)2000000000007001 (14.3)5 +AVSD51 (20.0)01 (20.0)00000000000051 (20.0)016 +TGA700000000000000070007 +SV500020000000000070008 +Others400020000000000060009Interrupt. of Ao (simple)1000000000000000100010 +VSD21001 (4.8)50002000000028001 (3.6)11 +DORV41 (25)02 (50)00000000000041 (25)02 (50)12 +Truncus3000000000000000300013 +TGA2000100000000000300014 +Others7001 (14.3)0000000000007001 (14.3)15Vascular ring1000121 (8.3)01 (8.3)90000000221 (4.5)01 (4.5)16PS0000100000000000100017PAIVS or critical PS303 (10.0)03 (10.0)2600030002000613 (4.9)03 (4.9)18TAPVR1000200000000000300019PAPVR ± ASD0000000000001000100020ASD0000000012000150002700021Cor triatriatum0000000000000000000022AVSD (partial)2000400010000000700023AVSD (complete)3200068001 (1.5)40000000104001 (1.0)24 +TOF or DORV3000131 (7.7)01 (7.7)60000000221 (4.5)01 (4.5)25 +Others31 (33.3)01 (33.3)40002000000091 (11.1)01 (11.1)26VSD (subarterial)200011000200020001700027VSD (perimemb./muscular)380001171 (0.9)03 (2.6)500010001611 (0.6)03 (1.9)28VSD + PS0000100000000000100029DCRV ± VSD0000000000000000000030Aneurysm of sinus valsalva1000000000001000200031TOF240001002 (2.0)02 (2.0)1300040001412 (1.4)02 (1.4)32PA + VSD260008300015000100012500033DORV27000551 (1.8)02 (3.6)140002000981 (1.0)02 (2.0)34TGA (simple)70001000100010001000035 +VSD70003000000000001000036 VSD + PS91 (11.1)01 (11.1)500020000000161 (6.3)01 (6.3)37Corrected TGA8000181 (5.6)01 (5.6)40000000301 (3.3)01 (3.3)38Truncus arteriosus20001 (5.0)10005000000026001 (3.8)39SV722 (2.8)03 (4.2)571 (1.8)03 (5.3)211 (4.8)0131 (33.3)01 (33.3)1535 (3.3)08 (5.2)40TA18000200001200010005100041HLHS812 (2.5)03 (3.7)19000300000001032 (1.9)03 (2.9)42Aortic valve lesion40002000400020001200043Mitral valve lesion0000000010000000100044Ebstein61 (16.7)02 (33.3)400010003000141 (7.1)02 (14.3)45Coronary disease11 (100.0)01 (100.0)00002000100041 (25.0)01 (25.0)46Others241 (4.2)01 (4.2)651 (1.5)01 (1.5)751 (1.3)01230001873 (1.6)03 (1.6)47Redo VSD000030003600010004000048PS release0000000010000000100049RV-PA conduit replace0000000000000000000050Others18001 (5.6)3600045000161 (6.3)01 (6.3)1151 (0.9)02 (1.7)Total94617 (1.8)1 (0.1)27 (2.9)1,00810 (1.0)018 (1.8)3512 (0.6)02822 (2.4)02 (2.4)2,38731 (1.3)1 (0.04)49 (2.1)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass, *PDA* patient ductus arteriosus, *VSD* ventricular septal defect, *DORV* double outlet right ventricle, *AVSD* atrioventricular septal defect, *TGA* transposition of great arteries, *SV* single ventricle, *Interupt. of Ao.* interrupted aortic arch, *PS* pulmonary stenosis, *PA-IVS* pulmonary atresia with intact ventricular septum, *TAPVR* total anomalous pulmonary venous return, *PAPVR* partial anomalous pulmonary venous return, *ASD* atrial septal defect, *TOF* tetralogy of Fallot, *DCRV* double-chambered right ventricle, *TA* tricuspid atresia, *HLHS* hypoplastic left heart syndrome, *RV-PA* right ventricle--pulmonary artery(3) Main procedureNeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1SP shunt1705 (2.9)09 (5.3)4259 (2.1)012 (2.8)581 (1.7)01 (1.7)100065415 (2.3)022 (3.4)2PAB3596 (1.7)010 (2.8)2503 (1.2)05 (2.0)1500020006269 (1.4)015 (2.4)3Bidirectional Glenn or hemi-Fontan ± α00002656 (2.3)06 (2.3)106002 (1.9)40003756 (1.6)08 (2.1)4Damus--Kaye--Stansel operation41 (25.0)0245202210000000703 (4.3)04 (5.7)5PA reconstruction/repair (including redo)9000991 (1.0)02 (2.0)108001 (0.9)18001 (5.6)2341 (0.4)04 (1.7)6RVOT reconstruction/repair162 (12.5)02 (12.5)107001 (0.9)2312 (0.9)02 (0.9)170003714 (1.1)05 (1.3)7Rastelli procedure31 (33.3)01 (33.3)442 (4.5)02 (4.5)1082 (1.9)03 (2.8)100001655 (3.0)06 (3.6)8Arterial switch procedure1545 (3.2)08 (5.2)231 (4.3)01 (4.3)600000001836 (3.3)09 (4.9)9Atrial switch procedure4000000020001000700010Double switch procedure000000001100000001100011Repair of anomalous origin of CA100060001400070002800012Closure of coronary AV fistula000010005001 (20.0)2400030001 (3.3)13Fontan/TCPC100030004084 (1.0)06 (1.5)262 (7.7)03 (11.5)4386 (1.4)09 (2.1)14Norwood procedure428 (19.0)1 (2.4)7 (16.7)787 (9.0)011 (14.1)101 (10.0)02 (20.0)000013016 (12.3)1 (8.1)20 (15.4)15Ventricular septation000072 (28.6)02 (28.6)40001000122 (16.7)02 (16.7)16Left side AV valve repair (including redo)0000661 (1.5)01 (1.5)631 (1.6)01 (1.6)111 (9.1)01 (9.1)1403 (2.1)03 (2.1)17Left side AV valve replace (including redo)11 (100)01 (100)151 (6.7)01 (6.7)412 (4.9)02 (4.9)20000774 (5.2)04 (5.2)18Right side AV valve repair (including redo)20001300034000300007900019Right side AV valve replace (including redo)00001000600080001500020Common AV valve repair (including redo)21 (50.0)01 (50.0)345 (14.7)05 (14.7)191 (5.3)01 (5.3)1000567 (12.5)07 (12.5)21Common AV valve replace (including redo)21 (50.0)01 (50.0)61 (16.7)01 (16.7)8001 (12.5)3000192 (10.5)03 (15.8)22Repair of supra-aortic stenosis100061 (16.7)01 (16.7)91 (11.1)01 (11.1)0000162 (12.5)02 (12.5)23Repair of subaortic stenosis (including redo)11 (100.0)01 (100.0)7001 (14)360004000481 (2.1)02 (4.2)24Aortic valve plasty ± VSD closure300012001 (8.3)24000400043001 (2.3)25Aortic valve replacement0000200022000230004700026AVR with annular enlargement100030001300061 (16.7)01 (16.7)231 (4.3)01 (4.3)27Aortic root replace (except Ross)00000000600050001100028Ross procedure0000300010000100014000Total77632 (4.1)1 (0.1)43 (5.5)1,52142 (2.8)055 (3.6)1,39815 (1.1)024 (1.7)2274 (1.8)06 (2.6)3,92293 (2.4)1 (0.03)128 (3.3)Values in parenthesis represent mortality %*SP* systemic pulmonary, *PAB* pulmonary artery banding, *PA* pulmonary artery, *RVOT* right ventricular outflow tract, *CA* coronary artery, *AV* *fustula* arteriovenous fistula, *TCPC* total cavopulmonary connection, *AV valve* atrioventricular valve, *VSD* ventricular septal defect, *AVR* aortic valve replacement

Abstract of the survey {#Sec1}
======================

We sent out survey questionnaire forms to the departments of each category in all 1,986 institutions (601 cardiovascular, 802 general thoracic and 582 esophageal) nationwide in early April 2013. The response rates in each category by the end of December 2013 were 97.0, 96.8, and 95.2 %, respectively. This high response rate has been keep throughout recent survey, and more than 95 % response rate in all fields in 2012 survey has to be congratulated.

2012 Final report {#Sec2}
=================

(A) Cardiovascular surgery {#Sec3}
--------------------------

First, we are very pleased with the high response rate to our survey of cardiovascular surgery (97.0 %), which definitely enhances the quality of this annual report. We very much appreciate the enormous effort put into completing the survey at each participating institution.

Figure [1](#Fig1){ref-type="fig"} shows the development of cardiovascular surgery in Japan over the last 26 years. Aneurysm surgery includes only operations for thoracic and thoracoabdominal aortic aneurysm. Pacemaker implantation includes only transthoracic implantation and transvenous implantation is excluded. The number of pacemaker and assist device implantation operations is not included in the total number of surgical operations. A total of 63,800 cardiovascular operations were performed at 583 institutions during 2012 alone and included 28 heart transplantations, which were restarted in 1999.Fig. 1Annual trend of in-patients with esophageal diseases, *EMR* endoscopic mucosal resection (including endoscopic submucosal)

The number of operations for congenital heart disease (9,558 cases) decreased slightly (3.1 %) compared with that of 2011 (9,859 cases), while there was 3.9 % increase when compared with the data of 10 years ago (9,202 cases in 2002). The number of operations for adult cardiac disease (20,913 cases in valvular heart disease, 16,752 cases in ischemic heart disease, 14,944 cases in thoracic aortic aneurysm and 1,663 cases for other procedures) increased compared with those of 2011 in all categories (9.1, 7.5, 5.8 and 5.1 %, respectively). During the last 10 years, the numbers of operations for adult heart disease increased constantly except for that of ischemic heart disease (81.0 % increase in valvular heart disease, 26.6 % decrease in ischemic heart disease, 112.4 % increase in thoracic aortic aneurysm, and 40.7 % increase in other procedures compared those of 2002). The concomitant coronary artery bypass grafting procedure (CABG) is not included in ischemic heart disease but included in other categories such as valvular heart disease in our study, then, the number of CABG still remained over 20,000 cases per year (21,569 cases) in 2012, which is 89.4 % of that in 2002 (24,135 cases).

Data for individual categories are summarized in tables through 1 to 7.

In 2012, 7,171 open-heart operations for congenital heart disease were performed with overall hospital mortality of 2.3 %. The number of operations for congenital heart disease was quite steady throughout these 10 years (maximum 7,386 cases in 2006), while overall hospital mortality decreased gradually from that of 3.6 % in 2002. In detail, the most common disease was atrial septal defect (1,331 cases), however, its number deceased to 71.7 % of that in 2002, which might be due to the recent development of catheter closure of atrial septal defect in Japan. Hospital mortality for complex congenital heart disease improved dramatically in the last 10 years such as interrupted aortic arch with ventricular septal defect (13.9 % in 2002 to 3.6 % in 2012), complete atrio-septal defect (4.2 to 3.2 %), Tetralogy of Fallot (3.8 to 1.1 %), transposition of the great arteries with and without ventricular septal defect (14.0 to 3.2 % and 7.4 to 2.6 %, respectively), single ventricle and tricuspid atresia (9.2 to 5.5 % and 3.9 to 0 %, respectively), and hypoplastic left heart syndrome (37.9 to 10.2 %). Right heart bypass surgery is now commonly performed (375 bidirectional Glenn procedures and 438 Fontan type procedures including total cavopulmonary connection) with acceptable hospital mortality (2.1 % in each procedure). Norwood type I procedure was performed in 130 cases with relatively low hospital mortality rate of 15.4 %.

As previously mentioned, the number of operations for valvular heart disease increased by 81 % in the last 10 years, and the hospital mortality associated with primary single valve replacement was 3.0 and 4.5 % for the aortic and the mitral position, while that for primary mitral valve repair was 1.3 %. However, hospital mortality rate for redo valve surgery was still high and was 9.3 and 6.7 % for aortic and mitral procedure, respectively. Finally, overall hospital mortality did not show any improvement during the last 10 years (3.1 % in 2002 and 3.2 % in 2012), which might be partially due to the recent progression of age of the patients. Repair of the valve became popular procedure (484 cases in the aortic, 6,002 cases in the mitral, and 4,947 case in the tricuspid), and mitral valve repair constituted 28.7 % of all valvular heart disease operation and 57.6 % of all mitral valve procedure (10,425 procedures), which are similar to those of the last 4 years and increased compared with those of 2002 (19.5 and 34.9 %, respectively). Aortic and mitral valve replacement with bioprosthesis were performed in 8,926 cases and 3,002 cases, respectively, with the number consistently increasing. The ratio of prostheses changed dramatically during the last 10 years, and the usage of bioprosthesis is 74.3 % at the aortic position (37.3 % in 2002) and 61.0 % at the mitral position (24.2 % in 2002). CABG as a concomitant procedure increased gradually to 23.9 % of operations for all valvular heart disease (12.1 % in 2002).

Isolated CABG was performed in 15,462 cases which were only 71.5 % of that of 10 years ago (2002), however, there was an increase of 8.5 % compared with that in 2011. Among these 15,462 cases, off-pump CABG was intended in 9,499 cases (61.4 %) with a success rate of 97.9 %, so final success rate of off-pump CABG was 60.2 %. The percentage of intended off-pump CABG was 55.2 % in 2003, and was increased to 60.3 % in 2004, then was kept over 60 % until now. Conversion rate from off-pump CABG to on-pump CABG of 2.1 % was just same as that in 2011. In 15,462 isolated CABG patients, 96.5 % of them received at least one arterial graft, while, all arterial graft CABG was performed in only 23.5 % of them.

The operative and hospital mortality rates associated with primary elective CABG procedures in 13,004 cases were 0.6 and 1.1 %, respectively. Similar data analysis of CABG including primary/redo and elective/emergency data was begun in 2003, and the operative and hospital mortality rates associated with primary elective CABG procedures in 2003 were 1.0 and 1.5 %, respectively, so operative results of primary CABG have been improved. However, hospital mortality of primary emergency CABG in 2,224 cases was 7.4 %, which was still high in spite of slight improvement compared with 9.7 % of hospital mortality rate in 2003. In comparison with data in 2003, the results of conversion improved both conversion rate (3.1 to 2.1 %) and hospital mortality (8.5 to 5.1 %).

A total of 1,274 patients underwent surgery for complications of myocardial infarction, including 413 operations for a left ventricular aneurysm or ventricular septal perforation or cardiac rupture and 296 operations for ischemic mitral regurgitation.

Operations for arrhythmia were performed mainly as a concomitant procedure in 3,992 cases with satisfactory mortality (1.8 % hospital mortality) including 3,771 MAZE procedures. MAZE procedure has become quite popular procedure when compared with that in 2002 (1,141 cases).

Operations for thoracic aortic dissection were performed in 6,266 cases. For 4,186 Stanford type A acute aortic dissections, hospital mortality was 10.6 %, which was similar to that in 2011 (11.1 %) and better than that in 2002 (15.5 %). Operations for a non-dissected thoracic aneurysm were carried out in 8,678 cases, with overall hospital mortality of 5.4 %, which was better than that in 2011 (6.7 %). The hospital mortality associated with unruptured aneurysm was 4.0 %, and that of ruptured aneurysm was 22.2 %, which remains markedly high.

The number of stent graft procedures remarkably increased recently. A total of 835 patients with aortic dissection underwent stent graft placement: thoracic endovascular aortic repair (TEVAR) in 723 cases, open stent grafting in 109 cases, and unspecified in 3 cases. The number of TEVAR for type B chronic aortic dissections increased from 359 cases in 2011 to 492 cases in 2012. The hospital mortality rates associated with TEVAR for type B aortic dissection were 7.3 % in acute cases and 2.6 % for chronic cases, respectively.

A total of 3,236 patients with non-dissected aortic aneurysm underwent stent graft placement with 18.8 % increase compared with that in 2011 (2,725 cases); TEVAR in 3,006 cases (23.6 % increase compared with that in 2011), open stent grafting in 226 cases (20.8 % decrease compared with that in 2011), and unspecified in 4 cases. The hospital mortality rates for TEVAR were 2.5 and 16.1 % for non-ruptured and ruptured aneurysm, respectively.

In summary, the total cardiovascular operations increased during 2012 by 3,516 cases, with steadily improving results in almost all categories compared with those in 2011.

**Table 2** Acquired (total, (1) + (2) + (4) + (5) + (6) + (7) + isolated ope. for arrhythmia in (3); 39,177(1) Valvular heart disease (total; 20,913)ValveCasesOperation30-day mortalityHospital mortalityRedoMechanicalBioprosthesisRoss procedureRepairWith CABGHospitalAfter discharge30-day mortalityHospital mortalityReplaceRepairReplaceRepairReplaceRepairCasesHospitalAfter dischargeIsolatedA9,6882,2197,07433922,316189 (2.0)6 (1.5)9 (0.1)0275 (3.0)6 (1.5)36520 (5.5)034 (9.3)M4,61772184703,04977345 (2.9)23 (0.8)1 (0.1)2 (0.1)71 (4.5)41 (1.3)35614 (3.9)024 (6.7)T312992211425 (5.0)2 (0.9)008 (7.9)5 (2.4)662 (3.0)06 (9.1)P180153100000010000A + MA1,38044488205421565(4.7)096(7.0)100M30338306948 (8.0)011 (11.0)A + TA400110281184515(3.8)029(7.3)55T32303742 (3.6)05 (9.1)M + TM3,3886349251,82929465(1.9)091(2.7)274T6503,33214 (5.1)026 (9.5)A + M + TA1,04032168903011737(3.6)051(4.9)76M26234804304 (5.3)05 (6.6)T0911,030Others70183801653(4.3)03(4.3)71 (14.3)01 (14.3)Total20,9135,05011,656511,4523,808455(2.2)12676(3.2)1,30965 (5.0)0112 (8.6)Number of redo cases is included in total case number of 18,713Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting, *A* aortic valve, *M* mitral valve, *T* tricuspid valve, *P* pulmonary valve(2) Ischemic heart disease (total, (A) + (B) + (C); 16,752)*(A) Isolated CABG (total; (a) + (b); 15,462)*(a-1) On-pump arrest CABG (total; 3,749)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft+SVGSVG onlyOthersCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD79001 (1.3)202 (10.0)02 (10.0)200000006662902VD4544 (0.9)05 (1.1)442 (4.5)02 (4.5)101 (10.0)01 (10.0)42 (50.0)02 (50.0)1113673403VD1,64813 (0.8)017 (1.0)20312 (5.9)014 (6.9)1200000001321,691400LMT1,00316 (1.6)020 (2.0)25513 (5.1)017 (6.7)142 (14.3)02 (14.3)11 (100.0)01 (100.0)1461,080470Uncertain0Total3,18433 (1.0)043 (1.4)52229 (5.6)35 (6.7)383 (7.9)3 (7.9)53 (60.0)3 (60.0)4553,1441500Kawasaki100001000000000007400Hemodialysis1937 (3.6)08 (4.1)409 (22.5)010 (25.0)400020001321790Values in parenthesis represent mortality %LMT includes LMT alone or LMT with other branch diseases. *CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft(a-2) On-pump beating CABG (total; 2,214)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft+SVGSVG onlyOthersCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD23001 (4.3)14001 (7.1)400041 (25.0)02 (50.0)2251802VD2352 (0.9)06 (2.6)657 (10.8)07 (10.8)111 (9.1)01 (9.1)3000652232513VD8058 (1.0)1 (0.1)16 (2.0)21120 (9.5)028 (13.3)12001 (8.3)1000107889330LMT5504 (0.7)09 (1.6)26427 (10.2)1 (0.4)36 (13.6)100002000139639480Total1,61314 (0.9)32 (2.0)55454 (9.7)72 (13.0)371 (2.7)2 (5.4)101 (10.0)2 (20.0)3331,7561241Kawasaki10001000000000001100Hemodialysis1582 (1.3)08 (5.1)465 (10.9)05 (10.9)3001 (33.3)300018176160Values in parenthesis represent mortality %LMT includes LMT alone or LMT with other branch diseases. *CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft(b) Off-pump CABG (total; 9,499)(The present section also includes cases of planned off-pump CABG in which, during surgery, the change is made to an on-pump CABG or on-pump beating-heart procedure)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft+SVGSVG onlyOthersCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD5821 (0.2)06 (1.0)672 (3.0)03 (4.5)400108000590485902VD1,4846 (0.4)012 (0.8)1353 (2.2)05 (3.7)182 (11.1)02 (11.1)50006309614103VD3,64511 (0.3)1 (0.03)31 (0.9)39014 (3.6)021 (5.4)2200031 (33.3)01 (33.3)7723,221612LMT2,49614 (0.6)024 (1.0)57423 (4.0)031 (5.4)2400061 (16.7)01 (16.7)8552,161750Total8,20732 (0.4)1 (0.01)73 (0.9)1,16642 (3.6)60 (5.1)1042 (1.9)2 (1.9)222 (9.1)2 (9.1)2,8476,3912362Kawasaki60001000100000007100Hemodialysis6597 (1.1)015 (2.3)9410 (10.6)017 (18.1)100000000163581190Values in parenthesis represent mortality %LMT includes LMT alone or LMT with other branch diseases. *CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft(c) Includes cases of conversion, during surgery, from off-pump CABG to on-pump CABG or on-pump beating-heart CABG (total; 197)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeA conversion to on-pump CABG arrest heart331 (3.0)01 (3.0)50000000000A conversion to on-pump beating-heart CABG1175 (4.3)06 (5.1)413 (7.3)03 (7.3)1000000Total1507 (4.7)07 (4.7)463 (6.5)3 (6.5)10000000Hemodialysis131 (7.7)01 (7.7)62 (33.3)2 (33.3)00000000Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting*(B) Operation for complications of MI (total; 1,274)*ChronicAcuteConcomitant operationCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeCABGMVPMVRInfarctectomy or aneurysmectomy35018 (5.1)029 (8.3)262 (7.7)03 (11.5)26310715VSP closure494 (8.2)07 (14.3)24053 (22.1)164 (26.7)89710Cardiac rupture141 (7.1)01 (7.1)22475 (33.5)085 (37.9)4024Mitral regurgitation 1) Papillary muscle rupture11000359 (25.7)011 (31.4)181023 2) Ischemic28518 (6.3)030 (10.5)284 (14.3)04 (14.3)26222548Others500071 (14.3)01 (14.3)200Total71441 (5.7)067 (9.4)560144 (25.7)1168 (30.0)674351100Values in parenthesis represent mortality %Acute, within 2 weeks from the onset of myocardial infarction*MI* myocardial infarction, *CABG* coronary artery bypass grafting, *MVP* mitral valve repair, *MVR* mitral valve replacement, *VSP* ventricular septal perforation*(C) TMLR (total; 16)*Cases30-day mortalityHospital mortalityHospitalAfter dischargeIsolated142 (14.29)02 (14.29)With CABG2000Total162 (12.5)02 (12.5)Values in parenthesis represent mortality %*TMLR* transmyocardial laser revascularization(3) Operation for arrhythmia (total; 4,183)Cases30-day mortalityHospital mortalityConcomitant operationIsolatedCongenitalValveIHDOthersMultiple combinationHospitalAfter discharge2 Categories3 CategoriesMaze3,93542 (1.1)062 (1.6)151973,47149319846224For WPW00000000000For ventricular tachyarrhythmia441 (2.3)02 (4.5)231327780Others20410 (4.9)013 (6.4)3391414318381Total4,18353 (1.3)077 (1.8)202393,62556322350825Values in parenthesis represent mortality %. Except for 20 isolated cases, all remaining 4,163 cases are doubly allocated, one for this subgroup and the other for the subgroup corresponding to the concomitant operations*WPW* Wolff--Parkinson--White syndrome, *IHD* ischemic heart disease(4) Operation for constrictive pericarditis (total; 195)CPB (+)CPB (−)Cases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospital96Total969 (9.4)018 (18.8)995 (5.1)09 (9.1)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass(5) Cardiac tumor (total; 628)Cases30-day mortalityHospital mortalityConcomitant operationHospitalAfter dischargeAVRMVRCABGOthersBenign tumor5536 (1.1)8 (1.4)1472558 Cardiac myxoma4052 (0.5)03 (0.7)431741 Papillary fibroelastoma470006207 Rhabdomyoma40000001 Others974 (4.1)05 (5.2)4289Malignant tumor752 (2.7)1 (1.3)6 (8.0)0028 Primary432 (4.7)1 (2.3)5 (11.6)0025 Metastatic32001 (3.1)0003Values in parenthesis represent mortality %*AVR* aortic valve replacement, *MVR* mitral valve replacement, *CABG* coronary artery bypass grafting(6) HOCM and DCM (total; 217)Cases30-day mortalityHospital mortalityConcomitant operationHospitalAfter dischargeAVRMVRMVPCABGMyectomy1334 (3.0)016 (12.0)67211212Myotomy60001030No-resection381 (2.6)07 (18.4)821133Volume reduction surgery of the left ventricle403 (7.5)04 (10.0)18247Total2178 (3.7)027 (12.4)77505222Values in parenthesis represent mortality %*HOCM* hypertrophic obstructive cardiomyopathy, *DCM* dilated cardiomyopathy, *AVR* aortic valve replacement, *MVR* mitral valve replacement, *MVP* mitral valve repair, *CABG* coronary artery bypass grafting(7) Other open-heart operation (total; 452)Cases30-day mortalityHospital mortalityHospitalAfter dischargeTotal45238 (8.4)053 (11.7)Values in parenthesis represent mortality %**Table 3** Thoracic aortic aneurysm (total; 14,944)(1) Dissection (total; 6,266)Replaced siteStanford typeAcuteChronicConcomitant operationRedoABABCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityAVPAVRMVPMVRCABGCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1. Ascending Ao.2,447190 (7.8)2 (0.1)232 (9.5)31 (33.3)01 (33.3)2225 (2.3)06 (2.7)81 (12.5)01 (12.5)2401341710125498 (16.3)08 (16.3)2. Aortic Root14928 (18.8)033 (22.1)0000687 (10.3)09 (13.2)4000211185142489 (18.8)011 (22.9)3. Ascending Ao.+Arch1,340116 (8.7)2 (0.15)150 (11.2)163 (18.8)03 (18.8)3028 (2.6)1 (0.3)18 (6.0)1074 (3.7)09 (8.4)1126110387904 (4.4)05 (5.6)4. Arch+Descending Ao.304 (13.3)04 (13.3)104 (40.0)05 (50.0)211 (4.8)01 (4.8)796 (7.6)09 (11.4)0100591 (11.1)02 (22.2)5. Aortic Root+Asc. Ao.+Arch9621 (21.9)1 (1.0)22 (22.9)000027000 (0.0)400018510113100006. Descending Ao.11001 (9.1)528 (15.4)011 (21.2)774 (5.2)06 (7.8)2178 (3.7)014 (6.5)14004386 (15.8)07 (18.4)7. Thoracoabdominal Ao.5000121 (8.3)02 (16.7)493 (6.1)03 (6.1)15113 (8.6)016 (10.6)00000434 (9.3)04 (9.3)8. Extra-anatomical bypass11001 (9.1)191 (5.3)02 (10.5)4000 (0.0)10000000000009. Stent graft^\*a^971 (1.0)01 (1.0)1206 (5.0)08 (6.7)1003 (3.0)05 (5.0)5188 (1.5)015 (2.9)53005992 (2.0)03 (3.0) 1) TEVARl^\*b^351 (2.9)01 (2.9)1106 (5.5)08 (7.3)863 (3.5)05 (5.8)4927 (1.4)013 (2.6)20000972 (2.1)03 (3.1) 2) Open stent620001000014000231 (4.3)02 (8.7)330052000  a) With total arch^\*c^3000400010004000100001000  b) Without total arch^\*d^59000600013000191 (5.3)02 (10.5)230051000 3) Unspecified0000000000003000000000000Total4,1863605 (0.12)444 (10.6)23224 (10.3)030 (12.9)86536 (4.2)1 (0.1)52 (6.0)98334 (3.5)042 (4.3)339326321629433529 (8.7)035 (10.4)Values in parenthesis represent mortality %*Ao* aorta, *AVP* aortic valve repair, *AVR* aortic valve replacement, *MVP* mitral valve repair, *MVR* mitral valve replacement, *CABG*. coronary artery bypass grafting, *TEVAR* thoracic endovascular aortic(aneurysm) repairAcute, within 2 weeks from the onset\*a = \*b + \*c + \*d + unspecified(2) Non-dissection (total; 8,678)Replaced siteUnrupturedRupturedConcomitant operationRedoCPB(−)Cases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityAVPAVRMVPMVRCABGCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1. Ascending Ao.1,18419 (1.6)1 (0.1)38 (3.2)507 (12.9)010 (20.0)1117556635159883 (3.4)011 (12.5)5001 (20.0)2. Aortic Root82416 (1.9)029 (3.5)314 (30.8)09 (29.0)1874484798910913 (11.9)024 (22.0)140003. Ascending Ao.+Arch2,10647 (2.2)387 (4.1)16832 (14.8)044 (26.2)26202282338898 (9.0)011 (12.4)29001 (3.4)4. Arch+Descending Ao.11110 (9.0)013 (11.7)72 (34.3)02 (28.6)0200893 (33.3)03 (33.3)90005. Aortic Root+Asc.Ao.+Arch935 (5.4)09 (9.7)21 (50.0)01 (50.0)1247319183 (16.7)04 (22.2)30006. Descending Ao.32315 (4.6)023 (7.1)8518 (19.7)021 (24.7)4100103313 (39.4)014 (42.4)150007. Thoracoabdominal Ao.36823 (6.3)033 (9.0)438 (24.3)010 (23.3)00004404 (10.0)05 (12.5)150008. Extra-anatomical bypass442 (4.5)03 (6.8)32 (66.7)02 (66.7)00004100091 (11.1)02 (22.2)9. Stent graft\*^a^2,88956 (1.9)1 (0.03)80 (2.8)34740 (12.9)1 (0.3)56 (16.1)68002019310 (5.2)014 (7.3)1,21237 (3.1)050 (4.1)1) TEVARl\*^b^2,67147 (1.8)1 (0.04)66 (2.5)33540 (13.7)1 (0.3)54 (16.1)6200818410 (5.4)014 (7.6)1,15237 (3.2)048 (4.2)2) Open stent2169 (4.2)014 (6.5)10002 (20.0)06001291 (11.1)0056002 (3.6) a) With total arch\*^c^785 (6.4)07 (9.0)400000003400031001 (3.2) b) Without total arch\*^d^1384 (2.9)07 (5.1)6002 (33.3)06009500025001 (4.0)3) Unspecified20020000000000000000Total7,942193 (2.4)5 (0.06)315 (4.0)736114 (15.5)1 (0.1)155 (22.2)3461,4631444764158057 (9.8)086 (14.8)1,31138 (3.0)054 (4.1)Values in parenthesis represent mortality %*Ao* aorta, *AVP* aortic valve repair, *AVR* aortic valve replacement, *MVP* mitral valve repair, *MVR* mitral valve replacement, *CABG* coronary artery bypass grafting, *TEVAR* thoracic endovascular aortic (aneurysm) repair\*a = \*b + \*c + \*d + unspecified**Table 4** Pulmonary thromboembolism (total; 121)Cases30-day mortalityHospital mortalityHospitalAfter dischargeAcute6511 (16.9)013 (20.0)Chronic56001 (1.8)Total12111 (9.1)014 (11.6)Values in parenthesis represent mortality %**Table 5** Assisted circulation (total; 1,875)SitesVADHeart--Lung assistDeviceResultsMethodResultsCentrifugalVASOthersNot weanedWeanedPCPSOthersNot weanedWeanedOn goingDeathTransplantAliveDeathsTransplantDeathsTransplantDeathsAlivePost-cardiotomy Left463210 (76.9)001 (10.0)0 Right30001 (33.3)0200Biventricle Right61025 (71.4)000051770268 (51.8)099 (19.1)220 Left250Congestive heart failure Left2338577032 (27.1)085 (4.2)3 Right000000000Biventricle Right2360518 (62.1)051 (9.1)088868439 (49.4)1139 (15.7)376 Left8192Respiratory failure755140 (53.3)015 (20.0)71Total6975627966 (32.0)0157 (3.4)31,480189747 (50.4)2253 (17.1)667Values in parenthesis represent mortality %*VAD* ventricular assist device, *VAS* ventricular assist system, *PCPS* percutaneous cardiopulmonary support**Table 6** Heart transplantation (total; 28)Cases30-day mortalityHospital mortalityHospitalAfter dischargeHeart transplantation281 (3.6)02 (7.1)Heart and lung transplantation0000Total281 (3.6)02 (7.1)Values in parenthesis represent mortality %**Table 7** Pacemaker + ICD (total; 6,971)PacemakerICDVA-VCRTCRTDICDInitial9422,715117299342Exchange7271,43932113197Unclear246000Total1,6714,200149412539*ICD* implantable cardioverter-defibrillator, *CRTD* cardiac resynchronization therapy device with incorporated ICD device

(B) General thoracic surgery {#Sec4}
----------------------------

The total number of operations reported in 2012 in general thoracic surgery has reached 72,899, which means an increase of 3,676 cases compared with the number of operations in 2011. This is largely owing to the steady increase in lung cancer surgery (31,301; 2009, 32,801; 2010, 33,878:2011, 35,667:2012).

Surgery for lung cancer consists more than 49 % of all the general thoracic surgery. Among lung cancer subtypes, adenocarcinoma comprises an overwhelming percentage of 69.4 % of the total lung cancer surgery, followed by squamous cell carcinoma of 19.0 %. Limited resection by wedge resection or segmentectomy was performed in 6,789 lung cancer patients, which is 19.0 % of the entire cases. Lobectomy was performed 26,079 patients, which is 73.1 % of the entire cases. Sleeve lobectomy was done in 429 patients. Pneumonectomy was done in 571 patients, which is only 1.6 % of the entire cases. VATS (video-assisted thoracic surgery) procedure is performed in 65.6 % among the total lung cancer surgeries in 2012. 123 patients died within 30 days after lung cancer surgery (30-day mortality rate 0.34 %), and 248 patients died without discharge (Hospital mortality rate 0.70 %). 30-day mortality rate in regard to procedures is 0.26 % in segmentectomy, 0.31 % in lobectomy, and 2.45 % in pneumonectomy.

Interstitial pneumonia was the leading cause of death after lung cancer surgery, followed by pneumonia, cardiovascular event, bronchopleural fistula, and respiratory failure.

7,403 patients with metastatic pulmonary tumor were operated in 2012 with steady increase similar to lung cancer surgery (6,248:2009, 6,748:2010, 7,210:2011). VATS was adopted in 5,828 cases, which comprises 78.7 % of the entire cases. Colorectal cancer was by far the leading primary malignancy indicated for resection of metastatic tumors.

73 tracheal tumors were operated in 2012. Adenoid cystic carcinoma and squamous cell carcinoma were frequent primary tracheal tumor.

409 tumors of pleural origin were operated in 2012. Diffuse malignant pleural mesothelioma was the most frequent histology. Extrapleural pneumonectomy was the most frequently chosen operative method (135 cases) with a hospital death of 6.7 %.

752 chest wall tumors were resected in 2012.

4,671 mediastinal tumors were operated in 2012. There were 2,151 thymic epithelial tumors (1,842 thymomas, 271 thymic carcinomas, and 38 thymic carcinoid), followed by 906 congenital cysts, 495 neurogenic tumors, and 231 germ cell tumors. 2,425 cases (51.9 %) were resected by VATS.

Thymectomy for myasthenia gravis was done in 446 patients, and 302 among them were associated with thymoma, indicating that thymectomy for non-thymomatous myasthenia gravis was done only in 144 patients. Advancement in medical control of myasthenia gravis by immunosuppressants might reduce indication of extended thymectomy for non-thymomatous myasthenia gravis. This possibility should be further examined.

2,250 operations for empyema were reported in 2012. There were 1,710 patients (76 %) with acute empyema and 540 patients with chronic empyema. Bronchopleural fistula was associated in 348 patients (20.4 %) with acute empyema and 274 patients (50.7 %) with chronic empyema. It should be noted that hospital mortality was as high as 12.1 % in patients of acute empyema with fistula.

14,410 operations for pneumothorax were reported in 2012. 13,555 operations (94.1 %) were performed by VATS, similarly to cases in 2011.

44 lung transplantations were reported in 2012. The number of the brain-dead donors is slightly increasing after revision of the law on organ transplantation.

The number of lung transplantation operation is still small compared to those in North America and European countries because of shortage of donors, but the number of brain-dead donors is increasing slowly in Japan after revision of the law of organ transplantation in 2010.

**Table 1** Total entry cases of general thoracic surgery during 2012Cases%Benign pulmonary tumor8631.2Primary lung cancer35,66748.9Other primary malignant pulmonary tumor3480.5Metastatic pulmonary tumor7,40310.2Tracheal tumor730.1Mesothelioma4090.6Chest wall tumor7521.0Mediastinal tumor4,6716.4Thymectomy for MG without thymoma3020.4Inflammatory pulmonary disease3,4054.7Empyema2,2503.1Bullous disease excluding pneumothorax5690.8Pneumothorax14,41019.8Chest wall deformity4150.6Diaphragmatic hernia including traumatic1120.2Chest trauma excluding diaphragmatic hernia3930.5Lung transplantation440.1Others8131.1Total72,899100.0**Table 2**1. Benign pulmonary tumorCases30-day mortalityHospital mortalityBy VATSHospitalAfter dischargeHamartoma421000371Sclerosing hemangioma10400084Papilloma90007Mucous gland adenoma bronchial50005Fibroma3400026Lipoma50004Neurogenic tumor1300010Clear cell tumor10001Leiomyoma130008Chondroma30003Inflammatory myofibroblastic tumor30002Pseudolymphoma2300017Histiocytosis110008Teratoma40002Others214000171Total863000719Values in parenthesis represent mortality %**Table 3**2. Primary malignant pulmonary tumorCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge2. Primary malignant pulmonary tumor36,015103 (0.3)15 (0.04)243 (0.7)Lung cancer35,667112 (0.3)11 (0.03)248 (0.7)23,411 Adenocarcinoma24,74948 (0.2)5 (0.02)84 (0.3) Squamous cell carcinoma7,11447 (0.7)4 (0.06)122 (1.7) Large cell carcinoma9173 (0.3)014 (1.5)* (LCNEC)4712 (0.4)06 (1.3)* Small cell carcinoma5912 (0.3)03 (0.5) Adenosquamous carcinoma6126 (1.0)111 (1.8) Carcinoma with pleomorphic, sarcomatoid or sarcomatous elements4732 (0.4)16 (1.3) Carcinoid19501 (0.5)0 Carcinomas of salivary gland type29000 Unclassified73000 Multiple lung cancer8031 (0.1)04 (0.5) Others1103 (2.7)04 (3.6) Unclear10 Wedge resection4,95211 (0.2)018 (0.4)4,135 Segmental excision3,7808 (0.2)2 (0.1)10 (0.3)2,654* (Sleeve segmental excision)160004* Lobectomy26,07972 (0.3)9 (0.03)178 (0.7)16,416* (Sleeve lobectomy)4294 (0.9)1 (0.2)7 (1.6)29* Pneumonectomy57114 (2.5)030 (5.3)75 *(Sleeve pneumonectomy)160000* Other bronchoplasty100003 Pleuropneumonectomy40001 Others2653 (1.1)05 (1.9)127 Unclear114 (36.4)7 (63.6)Sarcoma36001 (2.8)AAH143001 (0.7)Others169002 (1.2)Values in parenthesis represent mortality %**Table 4** Details of lung cancer operationTNMCasesc-Stage Ia20,510 Ib7,019 IIa2,712 IIb1,783 IIIa2,493 IIIb256 IV414 NA480 Total35,667Sex Male22,103 Female13,426 NA138 Total35,667Cause of death Cardiovascular25 Pneumonia52 Pyothorax8 Bronchopleural fistula25 Respiratory failure25 Pulmonary embolism3 Interstitial pneumonia71 Brain infarction or bleeding15 Others32 Unknown3 Total259p-Stage 0 (pCR)157 Ia17,804 Ib7,264 IIa3,011 IIb2,093 IIIa3,806 IIIb306 IV943 NA283 Total35,667Age \<204 20--2922 30--39223 40--491,001 50--593,630 60--6912,336 70--7914,299 80--894,100 ≥9050 NA2 Total35,667**Table 5**3. Metastatic pulmonary tumorCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge3. Metastatic pulmonary tumor7,4033 (0.04)09 (0.1)5,828 Colorectal3,639003 (0.1)2,910 Hepatobiliary/Pancreatic311001 (0.3)240 Uterine3801 (0.26)00302 Mammary456001 (0.2)386 Ovarian6800056 Testicular6400049 Renal600000500 Skeletal160000121 Soft tissue275000214 Otorhinolaryngological446000338 Pulmonary3843 (0.8)03 (0.8)238 Others620101 (0.2)474Values in parenthesis represent mortality %**Table 6**4. Tracheal tumorCases30-day mortalityHospital mortalityHospitalAfter discharge4. Tracheal tumor73001 (1.4)(A) Primary malignant tumor (histological classification) Squamous cell carcinoma4000 Adenoid cystic carcinoma19000 Mucoepidermoid carcinoma1000 Others1000 Total25000(B) Metastatic/invasive malignant tumor e.g. invasion of thyroid cancer23001 (4.3)(C) Benign tracheal tumor (histological classification) Papilloma1000 Adenoma2000 Neurofibroma2000 Chondroma1000 Leiomyoma0000 Others19000 Histology unknown0000 Total25000Operation Sleeve resection with reconstruction28000 Wedge with simple closure4000 Wedge with patch closure0000 Total laryngectomy with tracheostomy2001 (50.0) Others38000 Unknown1000 Total73001 (1.4)Values in parenthesis represent mortality %**Table 7**5. Tumor of pleural originCases30-day mortalityHospital mortalityHospitalAfter dischargeHistological classification Solitary fibrous tumor130000 Diffuse malignant pleural mesothelioma1985 (2.5)09 (4.5) Localized malignant pleural mesothelioma29001 Others52000 Total4093 (0.7)010 (2.4)Operative procedure Extrapleural pneumonectomy1355 (3.7)09 (6.7) Total pleurectomy22000 Total parietal pleurectomy0000 Partial pleurectomy0000 Exploratory thoracotomy0000 Others410 (0.0)00 Total1985 (2.5)09 (4.5)Values in parenthesis represent mortality %**Table 8**6. Chest wall tumorCases30-day mortalityHospital mortalityBy VATSHospitalAfter dischargePrimary malignant tumor1471 (0.68)01 (0.7)26Metastatic malignant tumor232002 (0.9)34Benign tumor373000199Total7521 (0.1)03 (0.4)259Values in parenthesis represent mortality %**Table 9**7. Mediastinal tumorCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge7. Mediastinal tumor4,6716 (0.13)07 (0.1)2,425 Thymoma\*1,8422 (0.1)02 (0.1)659 Thymic cancer2712 (0.7)03 (1.1)56 Thymus carcinoid3800015 Germ cell tumor2311 (0.4)01 (0.4)80 * Benign15900072* * Malignant721* (1.4)*01 (1.4)8* Neurogenic tumor495000412 Congenital cyst906000759 Goiter11500028 Lymphatic tumor2101 (0.5)01 (0.5)124 Excision of pleural recurrence of thymoma9300035 Others470000257\* Includes those with myasthenia gravisValues in parenthesis represent mortality %**Table 10**8. Thymectomy for myasthenia gravisCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge8. Thymectomy for myasthenia gravis446000171With thymoma3021 (0.3)02 (0.7)81Values in parenthesis represent mortality %**Table 11**9. Operation for non-neoplasmic disease(A) Inflammatory pulmonary diseaseCases30-day mortalityHospital mortalityHospitalAfter discharge9. Operation for non-neoplasmic disease22,367109 (0.5)2 (0.01)181 (0.8)Cases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge(A) Inflammatory pulmonary disease3,4054 (0.1)07 (0.2)2,556 Tuberculous infection10700070 Mycobacterial infection514000395 Fungal infection4394 (0.9)05 (1.1)218 Bronchiectasis9300060  Tuberculous nodule351000291  Inflammatory pseudo tumor1,007000812  Intrapulmonary lymph node175000161Others719002 (0.3)549Values in parenthesis represent mortality %**Table 12**9. Operation for non-neoplasmic disease(B) EmpyemaCases30-day mortalityHospital mortalityBy VATSHospitalAfter dischargeAcute empyema1,71029 (1.7)061 (3.6)1,142 With fistula34815 (4.3)042 (12.1)97 Without fistula1,34913 (1.0)018 (1.3)1,037 Unknown131 (7.7)01 (7.7)8Chronic empyema5405 (0.9)015 (2.8)133 With fistula2744 (1.5)010 (3.6)44 Without fistula2631 (0.4)05 (1.9)87 Unknown30002Total2,25034 (1.5)076 (3.4)1,275Values in parenthesis represent mortality %**Table 13**9. Operation for non-neoplasmic disease(C) Descending necrotizing mediastinitisCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge(C) Descending necrotizing mediastinitis926 (6.5)07 (7.6)50Values in parenthesis represent mortality %**Table 14**9. Operation for non-neoplasmic disease(D) Bullous diseaseCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge(D) Bullous disease569002 (0.4)443 Emphysematous bulla438002 (0.5)355 Bronchogenic cyst7400058 Emphysema with volume reduction surgery2200016 Others3500014Values in parenthesis represent mortality %*LVRS* lung volume reduction surgery**Table 15**9. Operation for non-neoplasmic disease(E) PneumothoraxCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge(E) Pneumothorax14,41037 (0.3)1 (0.01)53 (0.4)13,555*Spontaneous pneumothorax* Operative procedure  Bullectomy3,5883 (0.08)03 (0.08)3,400  Bullectomy with additional procedure7,7511 (0.01)01 (0.01)7,456   Coverage with artificial material7,3741 (0.01)01 (0.01)7,088   Parietal pleurectomy3400033   Coverage and parietal pleurectomy8500081   Others258000254  Others4753 (0.6)00432  Total11,8147 (0.1)04 (0.0)11,288*Secondary pneumothorax* Associated disease  COPD1,97719 (1.0)1 (0.1)25 (1.3)1,748  Tumorous disease923 (3.3)06 (6.5)75  Catamenial153000152  LAM382 (5.26)0233  Others (excluding pneumothorax by trauma)3339 (2.7)016 (4.8)258  Unknown31 Operative procedure  Bullectomy285 (17.9)08 (28.6)344  Bullectomy with additional procedure1,88119 (1.0)129 (1.5)1,656   Coverage with artificial material1,70714 (0.8)1 (0.06)23 (1.3)1,506   Parietal pleurectomy2100020   Coverage and parietal pleurectomy161 (6.3)01 (6.3)13   Others1374 (2.9)05 (3.6)117  Others3309 (2.7)012 (3.6)264  Unknown40003  Total2,24333 (1.5)1 (0.04)49 (2.2)2,267Values in parenthesis represent mortality %**Table 16**9. Operation for non-neoplasmic disease(F) Chest wall deformityCases30-day mortalityHospital mortalityHospitalAfter discharge(F) Chest wall deformity415000 Funnel chest393000 Others22000Values in parenthesis represent mortality %**Table 17**9. Operation for non-neoplasmic disease(G) Diaphragmatic herniaCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge(G) Diaphragmatic hernia1123 (2.7)04 (3.6)34 Congenital541 (1.9)02 (3.7)11 Traumatic382 (5.3)02 (5.3)7 Others3000016Values in parenthesis represent mortality %**Table 18**9. Operation for non-neoplasmic disease(H) Chest traumaCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge(H) Chest trauma39318 (4.6)1 (0.25)20 (5.1)127Values in parenthesis represent mortality %**Table 19**9. Operation for non-neoplasmic disease(I) Other respiratory surgeryCases30-day mortalityHospital mortalityBy VATSHospitalAfter discharge(I) Other respiratory surgery7277 (1.0)014 (1.9)392 Arteriovenous malformation\*951 (1.1)01 (1.1)73 Pulmonary sequestration12600068 Others5066 (1.2)013 (2.6)251\* Includes those with myasthenia gravisValues in parenthesis represent mortality %**Table 20**10. Lung transplantationCases30-day mortalityHospital mortalityHospitalAfter dischargeSingle lung transplantation from brain-dead donor16001 (6.3)Bilateral lung transplantation from brain-dead donor18000Lung transplantation from living donor10000Total of lung transplantation 44001 (2.3)Donor of living donor lung transplantation 17000Values in parenthesis represent mortality %**Table 21**11. Video-assisted thoracic surgeryCases30-day mortalityHospital mortalityHospitalAfter discharge11. Video-assisted thoracic surgery54,61683 (0.2)5 (0.01)141 (0.3)Values in parenthesis represent mortality %(Including thoracic sympathectomy 146)**Table 22**12. TracheobronchoplastyCases30-day mortalityHospital mortalityHospitalAfter discharge12. Tracheobronchoplasty5543 (0.5)1 (0.2)9 (1.6)Trachea105002 (1.9) Sleeve resection with reconstruction58000 Wedge with simple closure29001 Wedge with patch closure1000 Total laryngectomy with tracheostomy2001 Others15000Cardinal reconstruction7000Sleeve pneumonectomy16001 (6.3)Sleeve lobectomy3833 (0.8)1 (0.3)6 (1.6)Sleeve segmental excision12000Bronchoplasty without lung resection12000Others19000Values in parenthesis represent mortality %**Table 23**13. Pediatric surgeryCases30-day mortalityHospital mortalityHospitalAfter discharge13. Pediatric surgery4171 (0.2)01 (0.2)Values in parenthesis represent mortality %**Table 24**14. Combined resection of neighboring organ(s)Cases30-day mortalityHospital mortalityHospitalAfter discharge14. Combined resection of neighboring organ(s)1,0025 (0.5)3 (0.3)15 (1.5)(A) Primary lung cancer (organ resected) Aorta91 (11.1)01 (11.1) Superior vena cava35002 (5.7) Brachycephalic vein121 (8.3)01 (8.3) Pericardium1711 (0.6)03 (1.8) Pulmonary artery184002 (1.1) Left atrium331 (3.0)01 (3.0) Diaphragm94001 (1.1) Chest wall (including ribs)4942 (0.4)1 (0.2)12 (2.4) Vertebra30002 (6.7) Esophagus7000 Total1,0696 (0.6)1 (0.1)25 (2.3)(B) Mediastinal tumor (organ resected) Aorta2000 Superior vena cava551 (1.8)01 (1.8) Brachycephalic vein85001 (1.2) Pericardium2381 (0.4)01 (0.4) Pulmonary artery1000 Left atrium0000 Diaphragm24000 Chest wall (including ribs)16000 Vertebra6000 Esophagus3000 Lung290000 Total7202 (0.3)03 (0.4)Values in parenthesis represent mortality %**Table 25**15. Operation of lung cancer invading the chest wall of the apexCases30-day mortalityHospital mortalityHospitalAfter discharge15. Operation of lung cancer invading the chest wall of the apex128001 (0.01)Values in parenthesis represent mortality %Includes tumors invading the anterior apical chest wall and posterior apical chest wall (superior sulcus tumor, so-called Pancoast type)

(C) Esophageal surgery {#Sec5}
----------------------

During 2012 alone, a total of 12,315 patients with esophageal diseases were registered from 555 institutions (response rate: 95.4 %), affiliated to the Japanese Association for Thoracic Surgery and/or to the Japan Esophageal Society. Among these institutions, 20 or more patients underwent esophageal surgeries within the year of 2012 in 184 institutions (33.2 %), which shows definite shift of esophageal operations to high volume institutions when compared to the data of 2011 (22.9 %) (Table 1) Of 2,281 patients with a benign esophageal disease, 1,141 (50.0 %) patients underwent surgery, and 30 (1.3 %) patients underwent endoscopic resection, while 1,110 (48.7 %) patients did not undergo any surgical treatment. (Table 2) Of 10,034 patients with a malignant esophageal tumor, 7,859 (78.3 %) patients underwent resection, esophagectomy for 6,055 (60.3 %) and endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for 1,804 (18.0 %), while 2,175 (21.6 %) patients did not undergo any resection. (Tables 3, 4) The decrease of registered patients with nonsurgically treated benign esophageal diseases is obvious during 2011 and 2012. The patients registered, particularly those undergoing nonsurgical therapy for a malignant esophageal disease, have been increasing since 1990 (Fig. [1](#Fig1){ref-type="fig"}).

Among benign esophageal diseases (Table 2), esophageal varices, hiatal hernia, achalasia and esophagitis (including reflux esophagitis) were the most common conditions in Japan. On the other hand, spontaneous rupture of the esophagus, benign esophageal tumors and congenital esophageal atresia were common diseases which were surgically treated. The thoracoscopic and/or laparoscopic procedures have been widely adopted for benign esophageal diseases, in particular achalasia, hiatal hernia and benign tumors. Open surgery was performed in 828 patients with a benign esophageal disease with 30-day mortality in 5 (0.6 %), while thoracoscopic and/or laparoscopic surgery was performed for 233 patients with 0 (0.0 %) of the 30-day mortality The difference in these death rates between open and scopic surgery seems to be related to the conditions requiring open surgery.

The majority of malignant diseases were carcinomas (Table 3). Among esophageal carcinomas, the incidence of squamous cell carcinoma was 91.8 %, while that of adenocarcinomas including Barrett cancer was 5.7 %. The resection rate for patients with a squamous cell carcinoma was 77.6 %, while that for patients with an adenocarcinoma was 91.5 %.

According to location, cancer in the thoracic esophagus was the most common (Table 4). Of the 3,793 patients (37.8 % of total esophageal malignancies) having superficial esophageal cancers within mucosal and submucosal layers, 1,759 (46.3 %) patients underwent esophagectomy, while 1,802 (47.5 %) patients underwent EMR or ESD. The 30-day mortality rate and hospital mortality rate after esophagectomy for patients with a superficial cancer were 0.6 and 1.5 %, respectively. There was no EMR or ESD-related death. Advanced esophageal cancer invading deeper than the submucosal layer was observed in 6,231 (62.1 %) patients. Of the 6,231 patients with advanced esophageal cancer, 4,288 (68.8 %) underwent esophagectomy, with 0.8 % of the 30-day mortality rate, and with 2.4 % of the hospital mortality rate.

Multiple primary cancers were observed in 1,644 (16.4 %) of all the 10,034 patients with esophageal cancer. Synchronous cancer was found in 868 (52.9 %) patients, while metachronous cancer (found before esophageal cancer) was observed in 772 (47.0 %) patients. The stomach is the commonest site for both synchronous and metachronous malignancy followed by head & neck cancer (Table 4).

Among esophagectomy procedures, transthoracic esophagectomy through right thoracotomy was the most commonly adopted for patients with a superficial cancer as well as for those with an advanced cancer (Table 5). Transhiatal esophagectomy commonly performed in Western countries was adopted in only 4.4 % of patients having a superficial cancer who underwent esophagectomy, and in 2.0 % of those having an advanced cancer in Japan. The thoracoscopic and/or laparoscopic esophagectomy were adopted for 855 patients (48.6 %) with a superficial cancer, and for 1,193 patients (27.8 %) with an advanced cancer. The number of cases of thoracoscopic and/or laparoscopic surgery for superficial or advanced cancer has been increasing for these several years (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Annual trend of video-assisted esophagectomy for esophageal malignancy

Combined resection of the neighboring organs during resection of an esophageal cancer was performed in 334 patients (Tables 5, 6). Resection of the aorta together with the esophagectomy was performed in 2 cases. Tracheal and/or bronchial resection combined with esophagectomy was performed in 23 patients, with the 30-day mortality rate at 4.3 % and the hospital mortality rate at 13.0 %. Lung resection combined with esophagectomy was performed in 69 patients, with the 30-day mortality rate at 0 % and the hospital mortality rate at 1.4 %.

Salvage surgery after definitive (chemo-)radiotherapy was performed in 256 patients, with the 30-day mortality rate at 2.7 % and with the hospital mortality rate at 6.3 %. (Table 5).

Lastly, in spite of the efforts of the Committee to cover wider patient populations to this annual survey, the majority of the institutions which responded to the questionnaire were the departments of thoracic or esophageal surgery. It should be noted that larger number of patients with esophageal diseases should have been treated medically and endoscopically. We should continue our effort for complete survey through more active collaboration with the Japan Esophageal Society and other related societies. **Table 1** Distribution of number of esophageal operations in 2012 in each institutionEsophageal surgeryNumber of operations in 2012Benign esophageal diseasesMalignant esophageal diseaseBenign + malignant*0*262116861--422899995--934738110--19229810520--294454830--393323540--4903030≧5026271Total555555555

**Table 2** Benign esophageal diseasesOperation (+)Endoscopic resectionOperation (−)TotalNumber of patients30-day mortalityHospital mortalityTotalOpenT/L\*3Open surgeryT/L\*3TotalOpen surgeryT/L\*3TotalHospitalAfter dischargeTotalHospitalAfter discharge1. Achalasia19012961000000000402302. Benign tumor7437370000000003013117 (1) Leiomyoma46212200000000012967 (2) Cyst734000000000018 (3) Others21101100000000018342 (4) Not specified000000000000003. Diverticulum2822600000000014424. Hiatal hernia382284980000000001365185. Spontaneous rupture of the esophagus867971 (1.3)1 (1.3)000011 (1.3)09956. Esophago-tracheal fistula1413100000011 (7.7)011257. Congenital esophageal atresia351410000000 (0.0)000358. Congenital esophageal stenosis121110000000009219. Corrosive stricture of the esophagus11101000000000182910. Esophagitis, Esophageal ulcer343220000002 (5.9)2 (6.3)019723111. Esophageal varices23516781 (0.6)1 (0.6)00001 (0.4)1 (0.6)0608843 (1) Laparotomy312380000000 (0.0)0031 (2) Others0000000 (3) Sclerotherapy00000049749712. Others4030103 (10.0)3 (10.0)00003 (7.5)3 (10.0)05595Total1,1418282335 (0.6)5 (0.6)00008 (0.7)8 (1.0)0301,1102,281Values in parenthesis represent mortality %*T/L* thoracoscopic and/or laparoscopic**Table 3** Malignant esophageal diseases (histologic classification)Resection (+)Resection (−)TotalCarcinomas7,8232,1339,956 1. Squamous cell carcinoma7,0972,0449,141 2. Basaloid(-squamous) carcinoma861197 3. Carcinosarcoma36238 4. Adenocarcinoma in the Barrett's esophagus31526341 5. Other adenocarcinoma20022222 6. Adenosquamous carcinoma32234 7. Mucoepidermoid carcinoma404 8. Adenoid cystic carcinoma404 9. Endocrine cell carcinoma351348 10. Undifferentiated carcinoma8917 11. Others6410Other malignancies22729 1. Malignant non-epithelial tumors718 2. Malignant melanoma14519 3. Other malignant tumors112Not specified143549Total7,8592,17510,034Resection: including endoscopic resection**Table 4** Malignant esophageal disease (clinical characteristics)Operation (+)EMR or ESDOperation (−)TotalCases30-day mortalityHospital mortalityTotalHospitalAfter discharge1. Esophageal cancer6,05547 (0.8)45 (0.7)2 (0.0)131 (2.2)1,8042,17510,034Location0 (1) Cervical esophagus2152 (0.9)2 (0.9)08 (3.7)78164457 (2) Thoracic esophagus5,02243 (0.9)42 (0.8)1 (0.0)114 (2.3)1,5061,8458,373 (3) Abdominal esophagus5522 (0.4)1 (0.2)1 (0.2)8 (1.4)7878708 (4) Multiple cancers2610001 (0.4)11870449 (5) Others/not described50000241847Tumor depth (A) Superficial cancer1,75911 (0.6)10 (0.6)1 (0.1)26 (1.5)1,8022323,793 (B) Advanced cancer4,28836 (0.8)35 (0.8)1 (0.0)104 (2.4)01,9436,231 (C) Not specified820102. Multiple primary cancers9678 (0.8)7 (0.7)1 (0.1)20 (2.1)3643131,6441) Synchronous5583 (0.5)2 (0.4)1 (0.2)9 (1.6)138172868 (1) Head and neck1771 (0.6)1 (0.6)02 (1.1)6045282 (2) Stomach2210 (0.0)004 (1.8)3555311 (3) Others1372 (1.5)01 (0.7)1 (0.7)2754218 (4) Triple cancers2311 (4.3)02 (8.7)1618572) Metachronous4095 (1.2)5 (1.2)011 (2.7)225138772 (1) Head and neck822 (2.4)2 (2.4)02 (2.4)9330205 (2) Stomach1322 (1.5)2 (1.5)06 (4.5)5145228 (3) Others1711 (0.6)1 (0.6)02 (1.2)4843262 (4) Triple cancers240001 (4.2)321773Values in parenthesis represent mortality %*EMR* endoscopic mucosal resection (including endoscopic submucosal dissection)**Table 5** Malignant esophageal disease (surgical procedures)CasesOperation (+)EMR or ESD30-day mortalityHospital mortalityThoracoscopic and/or laparoscopic procedureHospitalAfter dischargeCases30-day mortalityHospital mortalityHospitalAfter dischargeSuperficial cancerEsophagectomy*1,75910 (0.6)1 (0.1)26 (1.5)8556 (0.7)013 (1.5)*1,802 (1) Transhiatal esophagectomy761 (1.3)02 (2.6)6000 (2) Transthoracic (rt.) esophagectomy and reconstruction1,3879 (0.6)1 (0.1)21 (1.5)7356 (0.8)012 (1.6) (3) Transthoracic (lt.) esophagectomy and reconstruction54001 (1.9)4000 (4) Cervical esophageal resection and reconstruction180003000 (5) Two-stage operation270007000 (6) Others184001 (0.5)76000 (7) Not specified1300124001 (4.2)Advanced cancer Esophagectomy*4,28835 (0.8)1 (0.0)104 (2.4)1,1938 (0.7)021 (1.8)*0 (1) Transhiatal esophagectomy841 (1.2)06 (7.1)8000 (2) Transthoracic (rt.) esophagectomy and reconstruction3,47922 (0.6)079 (2.3)1,0045 (0.5)018 (1.8) (3) Transthoracic (lt.) esophagectomy and reconstruction2272 (0.9)1 (0.4)3 (1.3)32000 (4) Cervical esophageal resection and reconstruction1202 (1.7)04 (3.3)6000 (5) Two-stage operation962 (2.1)05 (5.2)181 (5.6)01 (5.6) (6) Others/not specified2685 (1.9)06 (2.2)1162 (1.7)02 (1.7) (7) Not specified141 (7.1)01 (7.1)90 (0.0)00(Depth not specified)*8001 (12.5)*Combined resection of other organs*3342 (0.6)09 (2.7)* (1) Aorta2000 (2) Trachea, bronchus231 (4.3)03 (13.0) (3) Lung69001 (1.4) (4) Others2401 (0.4)05 (2.1)Salvage surgery*2567* *(2.7)016 (6.3)311 (3.2)04 (12.9)*35Values in parenthesis represent mortality %

**Table 6** Mortality after combined resection of the neighboring organsYearEsophagectomyCombined resectionAortaTracheobronchusLungOthersabc (%)abc (%)abc (%)abc (%)abc (%)19964,1941202.867342.862400.005024.007845.1319974,4411272.86100.0034514.715611.799433.1919984,8781362.79400.002900.007411.3512821.5619995,0151162.31500.002328.706800.0012210.8220005,350811.51200.002328.706900.009611.0420015,5211101.99100.002613.858333.619922.0220024,904661.353133.3320210.006300.006311.5920034,639450.97000.002428.335800.008811.1420044,739641.35200.001700.005958.4711921.6820055,163521.01100.001119.096711.497311.3720065,236631.20000.001700.006223.2312232.4620074,990601.20000.002514.004412.2713821.4520085,124631.23000.001715.884812.0818500.0020095,260631.20000.0019210.535823.4521131.4220105,180450.87200.003300.005800.0024552.0420115,430380.70400.002600.004100.0017952.7920126,055470.78200.002314.356900.0024010.42Total86,1191,0401.2126415.38273165.86753162.121,220231.89*a* number of patients who underwent the operation, *b* number of patients died within 30 days after operation, *c* % ratio of b/a, i.e., direct operative mortalityFig. 1General thoracic surgery
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